Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate

Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate

Arianne N Sweeting,1 Eddy Tabet,1 Ian D Caterson,1,2 Tania P Markovic1,2 1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 2Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, NSW, Australia Abstract: The US Food and D...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sweeting AN, Tabet E, Caterson ID, Markovic TP
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/a56e0dd14d9f45b49aa2b9cff1739cda
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a56e0dd14d9f45b49aa2b9cff1739cda
record_format dspace
spelling oai:doaj.org-article:a56e0dd14d9f45b49aa2b9cff1739cda2021-12-02T00:28:07ZManagement of obesity and cardiometabolic risk – role of phentermine/extended release topiramate1178-7007https://doaj.org/article/a56e0dd14d9f45b49aa2b9cff1739cda2014-02-01T00:00:00Zhttp://www.dovepress.com/management-of-obesity-and-cardiometabolic-risk-ndash-role-of-phentermi-a15775https://doaj.org/toc/1178-7007 Arianne N Sweeting,1 Eddy Tabet,1 Ian D Caterson,1,2 Tania P Markovic1,2 1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 2Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, NSW, Australia Abstract: The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release topiramate (phentermine/topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA's approval of both phentermine/topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention. Keywords: obesity, phentermine/topiramate extended release, safety and efficacy, reviewSweeting ANTabet ECaterson IDMarkovic TPDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2014, Iss default, Pp 35-44 (2014)
institution DOAJ
collection DOAJ
language EN
topic Specialties of internal medicine
RC581-951
spellingShingle Specialties of internal medicine
RC581-951
Sweeting AN
Tabet E
Caterson ID
Markovic TP
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
description Arianne N Sweeting,1 Eddy Tabet,1 Ian D Caterson,1,2 Tania P Markovic1,2 1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 2Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, NSW, Australia Abstract: The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release topiramate (phentermine/topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA's approval of both phentermine/topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention. Keywords: obesity, phentermine/topiramate extended release, safety and efficacy, review
format article
author Sweeting AN
Tabet E
Caterson ID
Markovic TP
author_facet Sweeting AN
Tabet E
Caterson ID
Markovic TP
author_sort Sweeting AN
title Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
title_short Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
title_full Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
title_fullStr Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
title_full_unstemmed Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
title_sort management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/a56e0dd14d9f45b49aa2b9cff1739cda
work_keys_str_mv AT sweetingan managementofobesityandcardiometabolicriskndashroleofphentermineextendedreleasetopiramate
AT tabete managementofobesityandcardiometabolicriskndashroleofphentermineextendedreleasetopiramate
AT catersonid managementofobesityandcardiometabolicriskndashroleofphentermineextendedreleasetopiramate
AT markovictp managementofobesityandcardiometabolicriskndashroleofphentermineextendedreleasetopiramate
_version_ 1718403758597079040

Ejemplares similares